Review of Industrial Organization

, Volume 27, Issue 4, pp 329–350 | Cite as

How do Brands’ “Own Generics” Affect Pharmaceutical Prices?

Article

Abstract

This paper examines the price effects of generic drugs that are produced by brand-name drug firms and that are labeled, priced, and marketed to compete against independent generics. The strategy of introducing such “pseudo-generics” – also known as “authorized generics” – has raised some antitrust concerns. One defense of this strategy has been that the additional competition created by pseudo-generics should lead to lower prices. This paper develops a simple model to show that pseudo-generics can be expected to have exactly the opposite effect. It then examines empirical evidence on this point from the Canadian pharmaceutical market, showing that there appears to be a positive relationship between drug prices and the share of generic sales made by the brand’s own pseudo-generic.

Keywords

Competition generics pharmaceuticals 

JEL Classifications

L12 I18 

References

  1. Anis, A.H. 1992‘Pharmaceutical Prices with Insurance Coverage and Formularies’Canadian Journal of Economics25420437Google Scholar
  2. Anis, A.H., Guh, D.P., Woolcott, J.W. 2003‘Lowering Generic Drug Prices: Less Regulation Equals More Competition’Medical Care41135141CrossRefGoogle Scholar
  3. Aronsson, T., Bergman, M., Rudholm, N. 2001‘The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Data’Review of Industrial Organization19425435CrossRefGoogle Scholar
  4. Bae, J.P. 1997‘Drug Patent Expirations and the Speed of Generic Entry’Health Services Research3287101Google Scholar
  5. Bound, S., JaegerD.A. Baker, R. 1995‘Problems with Instrumental Variables Estimation when the Correlation between the Instruments and the Endogenous Explanatory Variable is Weak’Journal of the American Statistical Association90443450Google Scholar
  6. Caves, R., Whinston, M., Hurwitz, M. 1991‘Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry’Brookings Papers: Microeconomics1991148Google Scholar
  7. Ferrandiz, J.M. 1999‘The Impact of Generic Goods in the Pharmaceutical Industry’Health Economics8599612Google Scholar
  8. Ganther, J.M., Kreling, D.H. 2000‘Consumer Perceptions of Risk and Required Cost Savings for Generic Prescription Drugs’Journal of the American Pharmaceutical Association40378383Google Scholar
  9. Grabowski, H., Vernon, J. 1992‘Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act’Journal of Law and Economics35331350CrossRefGoogle Scholar
  10. Hollis, A. 2002‘The Importance of Being First: Evidence from Canadian Generic Pharmaceuticals’Health Economics11723734CrossRefGoogle Scholar
  11. Hollis, A. 2003‘The Anti-Competitive Effects of Brand-Controlled ‘Pseudo-Generics’ in the Canadian Pharmaceutical Market’Canadian Public Policy292131Google Scholar
  12. Jambulingam, T., Kreling, D.H. 1995‘Relationship between the Number of Firms and Generic Price CompetitionJournal of Research in Pharmaceutical Economics63960Google Scholar
  13. Johnson, J., Myatt, D. 2003‘Multiproduct Quality Competition: Fighting Brands and Product Line Pruning’American Economic Review93748774Google Scholar
  14. Kamien, M.I., Zang, I. 1999‘Virtual Patent Extension by Cannibalization’Southern Economic Journal66117131Google Scholar
  15. Kong, Y. 2004‘The Price Premium of Generic to Brand-Names and Pharmaceutical Price Index’Applied Economics36731737CrossRefGoogle Scholar
  16. Kong, Y, Seldon, J. 2004‘Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets’Review of Industrial Organization257186CrossRefGoogle Scholar
  17. Morton, F.S. 1999‘Entry Decisions in the Generic Pharmaceutical Industry’Rand Journal of Economics30421440Google Scholar
  18. Morton, F.S. 2002‘Horizontal Integration between Brand and Generic Firms in the Pharmaceutical Industry’Journal of Economics and Management Strategy11135168CrossRefGoogle Scholar
  19. Pammolli, F., Magazzini, L., Orsenigo, L. 2002‘The Intensity of Competition after Patent Expiry in Pharmaceuticals: A Cross-Country Analysis’Revue d’Economie Industrielle99107131Google Scholar
  20. Salop S. (1985) ‘Practices that (credibly) Facilitate Oligopoly Coordination’, in J. Stiglitz et al., (eds.), New Developments in Market Structure. Cambridge: MIT Press, pp. 265–290.Google Scholar
  21. Staiger, D., Stock, J.H. 1997‘Instrumental Variables Regression with Weak Instruments’Econometrica6557586Google Scholar
  22. Suh, D.C., Manning, W.G.,Jr., Schondelmeyer, S., Hadsall, R.S. 2000‘Effect of Multiple-Source Entry on Price Competition after Patent Expiration in the Pharmaceutical Industry’Health Services Research35529547Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.Department of Economics and Institute of Health EconomicsUniversity of CalgaryCalgaryCanada

Personalised recommendations